Last edition
News about "advanced solid tumours"
Daiichi Sankyo has dosed the first patient in a phase 1 clinical trial of DS3610, its investigational STING agonist Antibody Drug Conjugate (ADC), marking a key step in advancing novel immunotherapy approaches for patients with advanced solid tumours.
Advanced Solid Tumours | 12/11/2025 | By Dineshwori
SPARC Submits IND Application for SBO-154 to USFDA
Sun Pharma Advanced Research Company Ltd. (SPARC) has submitted an IND application to the US FDA for SBO-154, a novel antibody-drug conjugate (ADC) targeting advanced solid tumours.
Advanced Solid Tumours | 31/03/2025 | By Aishwarya | 237
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy